RIOK3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL141930	0.90	2/20
SCHEMBL142206	0.85	2/20
SCHEMBL144842	0.80	2/20
SCHEMBL144192	0.75	2/20
SCHEMBL144525	0.71	2/20
SCHEMBL141676	0.69	2/20
SCHEMBL145500	0.69	2/20
SCHEMBL144281	0.68	2/20
SCHEMBL141372	0.68	2/20
SCHEMBL145902	0.67	2/20
SCHEMBL144785	0.67	2/20
SCHEMBL144209	0.62	2/20
SCHEMBL144321	0.61	2/20
SCHEMBL144930	0.60	2/20
SCHEMBL144687	0.60	2/20
SCHEMBL143493	0.59	2/20
SCHEMBL143779	0.59	2/20
SCHEMBL145149	0.57	2/20
SCHEMBL141123	0.55	2/20
SCHEMBL142779	0.55	2/20

Clinical trials — most relevant to RIOK3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer	PHASE2	COMPLETED
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer	PHASE1/PHASE2	COMPLETED
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma	PHASE2	COMPLETED
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas	PHASE1/PHASE2	COMPLETED
Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula	PHASE2	COMPLETED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients	PHASE1	UNKNOWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Better Delineation of CDK13 Related Phenotype and Epigenetic Signature.	nan	UNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Biomarkers in Samples From Patients With Endometrial Cancer	nan	WITHDRAWN
Study of the Pathophysiological Mechanisms Involved in Bleeding Events	nan	COMPLETED
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients	nan	COMPLETED
Molecular Analysis of Thoracic Malignancies	nan	ENROLLING_BY_INVITATION
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED
MEHMO Natural History and Biomarkers	nan	RECRUITING
Semen Analysis Changes in Covid-19 Positivepatients	nan	COMPLETED
Diagnosis of Prader-Willi Syndrome and Angelman Syndrome	nan	COMPLETED
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a RIOK3 binder may also engage these)

Protein	Name	Similarity
Q1RMT7	—	1.000	Q1RMT7 →
Q9DBU3	—	1.000	Q9DBU3 →
Q922Q2	—	0.981	Q922Q2 →
Q3UM18	—	0.979	Q3UM18 →
Q2YDM7	—	0.979	Q2YDM7 →
Q8N1G2	—	0.979	Q8N1G2 →
P70531	—	0.979	P70531 →
Q5BJT6	—	0.979	Q5BJT6 →
Q5R981	—	0.979	Q5R981 →
EEF2K	Eukaryotic elongation factor 2 kinase	0.978	landscape →
Q803R5	—	0.978	Q803R5 →
Q5U2Z5	—	0.978	Q5U2Z5 →
Q9DBC3	—	0.977	Q9DBC3 →
Q8IYB8	—	0.977	Q8IYB8 →
Q3ZBT2	—	0.976	Q3ZBT2 →
Q9NVU0	—	0.976	Q9NVU0 →
Q91WR3	—	0.976	Q91WR3 →
F1ND48	—	0.976	F1ND48 →
Q8CCP0	—	0.976	Q8CCP0 →
Q8R424	—	0.976	Q8R424 →
Q6NY89	—	0.976	Q6NY89 →
Q8BW10	—	0.976	Q8BW10 →
Q7ZXX9	—	0.975	Q7ZXX9 →
Q5U2X1	—	0.975	Q5U2X1 →
Q5ZKK7	—	0.975	Q5ZKK7 →
Q8VI84	—	0.975	Q8VI84 →
A4IID4	—	0.975	A4IID4 →
Q80YD1	—	0.975	Q80YD1 →
Q5RBB3	—	0.975	Q5RBB3 →
BRAP	BRCA1-associated protein	0.975	landscape →